Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Control Blood Sugar with Two Key "Sugar" Partners 1
doi:10.1006/exer.2000.0970
Glucose Lowering Liraglutide was the first long-acting GLP-1RA to become available for the treatment of T2D, receiving market authorization in 2009 in the EU (137), 4 years after the short-acting GLP-1RA, exenatide, was first approved in the US (138)
95% CI, -1.7 to -0.5 per 1000 person-years
US$ 21.92
US$ 27.56
US$ 21.26
US$ 27.61
US$ 22.61
US$ 23.38
